<DOC>
	<DOCNO>NCT00019058</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs pentoxifylline hydroxyurea may make tumor cell sensitive radiation therapy . PURPOSE : Phase I trial study effectiveness radiation therapy plus pentoxifylline hydroxyurea treat patient high-grade astrocytoma glioblastoma .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Glioblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose pentoxifylline administer hydroxyurea course cranial radiotherapy patient glioblastoma multiforme . II . Determine toxicity regimen patient . III . Measure PTX level plasma CSF order ass whether therapeutic drug exposure ( e.g. , 0.4-2.0 mM/24 hour ) achieve acceptable level toxicity . IV . Assess local control glioblastoma patient treat regimen . V. Determine response surround normal brain patient treated regimen . VI . Determine survival patient treat regimen . OUTLINE : This dose escalation study pentoxifylline ( PTX ) . Patients receive hydroxyurea ( HU ) PTX IV continuously 5 day week concurrently cranial radiotherapy twice daily , 5 day week , 4 week absence disease progression unacceptable toxicity . The first cohort 3 patient treated radiotherapy HU alone . Subsequent cohort 3-6 patient receive HU radiotherapy plus escalating dos PTX maximum tolerate dose PTX determine serum CSF drug concentration reach 0.4-2.0 mM 6 consecutive patient acceptable toxicity . The MTD define dose immediately precede 2 6 patient experience dose-limiting toxicity . Patients follow 1 week , 1 3 month , every 3 month 2 year , every 4 month 5 year . PROJECTED ACCRUAL : A maximum 24-34 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven grade IV astrocytoma glioblastoma multiforme confine 1 hemisphere brain Confirmation histology NIH neuropathology review require MRI CT complete within 3 week initial evaluation No clinically apparent leptomeningeal metastases No uncontrolled seizure despite standard anticonvulsant therapy No history epilepsy diagnose year glioblastoma PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 80100 % OR ECOG 01 Life expectancy : More 3 month Hematopoietic : WBC least 3,500/mm3 Absolute granulocyte count least 900/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL No hematologic disease require treatment Hepatic : Liver function test great 2.5 time upper limit normal No hepatic disease require treatment Renal : Creatinine great 1.3 mg/dL OR Creatinine clearance least 95 mL/min No renal disease require treatment Cardiovascular : No history hospitalization medication : Cardiovascular disease LVEF 45 % le Myocardial infarction Arrhythmia Coronary artery disease Angina Congestive heart failure Stroke No thromboembolic disease require treatment Pulmonary : No history hospitalization medication chronic obstructive pulmonary disease asthma Other : No peptic ulcer disease inflammatory bowel disease within past 2 year No document history intolerance methylxanthines ( e.g. , allergic serious adverse reaction ) No history psychiatric medical illness would preclude therapy No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No contraindication serial CT MRI ( e.g. , logistical problem , noncompliance , contrast allergy ) Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Prior biopsy subtotal neartotal resection allow At least 710 day 3 month since prior surgery and/or biopsy Other : No recent methylxanthinecontaining medication No concurrent anticoagulant methylxanthines ( e.g. , aspirin , nonsteroidal antiinflammatory drug , warfarin , heparin , theophylline , aminophylline , theobromine ) preexist medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>